STRATEC SE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 41.65 EUR | +3.74% |
|
+3.74% | -8.56% |
| 04-26 | STRATEC BIOMEDICAL SYSTEMS AG : Berenberg reiterates its Neutral rating | ZD |
| 04-26 | STRATEC BIOMEDICAL SYSTEMS AG : Warburg Research remains Neutral | ZD |
| Sales 2024 * | 276M 295M 23.6B | Sales 2025 * | 297M 317M 25.4B | Capitalization | 506M 541M 43.35B |
|---|---|---|---|---|---|
| Net income 2024 * | 19M 20.32M 1.63B | Net income 2025 * | 25M 26.73M 2.14B | EV / Sales 2024 * | 2.33 x |
| Net Debt 2024 * | 137M 147M 11.73B | Net Debt 2025 * | 75.66M 80.89M 6.48B | EV / Sales 2025 * | 1.96 x |
| P/E ratio 2024 * |
25.4
x | P/E ratio 2025 * |
19.6
x | Employees | 1,480 |
| Yield 2024 * |
2.31% | Yield 2025 * |
2.18% | Free-Float | 59.43% |
More Fundamentals
* Assessed data
More news
Latest transcript on Stratec SE
More recommendations
More press releases
| 1 day | +3.74% | ||
| 1 week | +3.74% | ||
| Current month | +3.61% | ||
| 1 month | -1.77% | ||
| 3 months | -1.77% | ||
| 6 months | +7.76% | ||
| Current year | -8.56% |
1 week
39.00
45.00
1 month
36.2545.00
Current year
36.2546.00
1 year
36.0069.00
3 years
36.00147.40
5 years
36.00147.40
10 years
32.10147.40
| Managers | Title | Age | Since |
|---|---|---|---|
Marcus Wolfinger
CEO | Chief Executive Officer | 56 | 28/02/98 |
Robert Siegle
DFI | Director of Finance/CFO | 56 | 30/04/98 |
Jan Keppeler
IRC | Investor Relations Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Frank Hiller
BRD | Director/Board Member | 57 | 28/05/19 |
Georg Heni
CHM | Chairman | 66 | 19/05/22 |
Rolf Vornhagen
BRD | Director/Board Member | 70 | 20/07/20 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.86% | 125 M€ | -.--% | ||
| 0.34% | 17 M€ | -.--% | - | |
| 0.01% | 773 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 41.65 | +3.74% | 18,423 |
| 25/04/24 | 40.15 | -3.25% | 40,381 |
| 24/04/24 | 41.5 | +0.24% | 16,531 |
| 23/04/24 | 41.4 | +3.24% | 6,321 |
| 22/04/24 | 40.1 | -0.12% | 3,839 |
Delayed Quote Xetra, April 26, 2024 at 04:35 pm
More quotes
Stratec SE is a Germany-based company engaged in the development and manufacture of fully automated systems based on its own patented technologies for its partners in the fields of in-vitro diagnostics and life sciences in Germany and internationally. Its business activities are divided into three segments: Instrumentation, which designs and manufactures fully automated analyzer systems for its clinical diagnostics and biotechnology customers; Diatron, which offers systems, system components, consumables, and tests for the low throughput hematology and clinical chemistry applications, and Consumables, which develops and sells scientific materials, such as nucleic acid purification and designs and produces smart consumables in the fields of diagnostics, life sciences, and medical technology. In addition, the Company develops workflow software for networking various analyzer systems, as well as develops and sells scientific materials and technologies.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
41.65
EUR
Average target price
43.33
EUR
Spread / Average Target
+4.04%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -8.56% | 541M | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +0.65% | 63.06B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B |
- Stock Market
- Equities
- SBS Stock
